ALT

dontslambro

They really gonna just ALT F4 the whole thing?

elpresidentedeljunta

I am a little disappointed of us all that no one seems to have made an ALT account to have the CEO pump a pennystock they own or have him say something embarrassing on the earnings call. We´re all just after the flair "Famous through Grindr" ...

Full_Pear449

I Traded on a Fixed Income Prop Desk within shouting distance to the Risk/Arb Desk , for a Firm that basically avoided most of this mess, Primary Dealer. What you don't know is the Lehman had an heavy exposure to CMBS where Valuations are Suspect. They moved their ALT-A loan into RMBS, again different valuations from reality. Much of this MBS portfolio fell under "Level III" accounting. This meant the assets were highly illiquid, had no active market pricing, and their value was calculated using Lehman's internal models, which severely overstated their worth as the housing market collapsed. The other neat trick was the use of REPO 105 and Repo 108. Repo 108- temporarily removing assets from the balance sheet by over-collateralizing transactions at 108% to record them as sales rather than loans. REPO 105- Reclassify short-term loans as sales. It involved moving about $50 billion of assets off the balance sheet temporarily to hide debt and make the firm look healthier right before reporting dates. One other interesting segment of Lehamn was that their Distressed Debt/Convertible desk had a sheet of about $600mm and made $2BLN in 2007. Basically on CDS, shorting their own and others heavy in the MBS market DEBT.

Ok_Individual5676

a better biotech imo would be ALLO, ALT or VKTX

Alive_Bid7229

He can’t take the red. Give him the blue screen of death so he can CTRL+ALT+DEL and reset his portfolio.

D0lph1nnnnn

Try ALT+Z to undo

Bitter_Pea_4716

Because Elon has a cult following of middle aged men who have parasocial relationship with him. This collective seems to adore the man. He says DOGE to the moon on twitter. People buy. Some people make money. Some do not. Those that do, now believe the man to be genius.  So they buy his Tesla's. They are blindsided by the vehicles clear flaws as they have developed a taste for the Elon.  They talk to people about Elon like he's their neighbour who lives across the road. They talk to insurance sales people about how Elon can get them parts after a single phone call. They tell those people how The Elon tastes. Those people want to savour that same flavour. The Elon strikes. The Elon hits CTRL ALT DELETE and says begone rug. Those people are fine with this. Because Elon is a genius and he has a plan. He would never do anything bad to these people. He will make them their money back. So the man starts larping as a cop and stripping the US people of their securities entitlements. The people are okay with this. Because Elon has a rocket company and he's cool because he smoked a joint with Joe rogan.  So Elon released space x stock to the public. the people are throbbing at Elon's image and they want to ride their respective rockets higher than its been brfore.  Some they bruise their knees, open their mouths wide, and pray their daddy will take them to the moon with him.  Once you have been exposed to these Elon lover individuals in person, you will understand that Elon is a beacon of hope or opportunity to riches for them. And no other beacon exists in these peoples lives. Unless the man dies, his companies' stock will follow what he says on twitter rather than performance 

GuyFieriFrostedTips

🥭 settles with himself as agent of Iran (because everyone is talking about how great of an Iyatollah he’d be but he said no no no I, I mean he, can’t do that. But he’d be great as it, you better believe it. It’s a great settlement. Iran gives straight to the new 🥭 and Musk ALT COIN. A great investment. A real win win…

jraiv420

Bol cope use ALT+I to flip charts

Difficult-Dark6837

Why ALT??

Xyz_83

SLS, AXSM, NRPX, ALT, MIST This is not financial advise, just thoughts and wishfull thinking. Do your own due diligence.

Vasuuuuu

Went -5% at open then +.5% and ALT+F4 everything. Came back at 1 PM and feeling much better about my decisions.

SignificanceNo3295

Yes, this is the sign to buy what you having been thinking of buying. The top is illusionary, there's always another ALT and that's when you will exit right before everything crashes.

Used_Salamander_3532

Altimmune (ALT) just closed a big $225M oversubscribed funding round in late April, giving the company a solid runway to push its lead drug pemvidutide into Phase 3 for MASH. With Q1 earnings coming up on May 13, the stock looks primed for a bounce back toward the $5–6 zone as the financing overhang clears and investors focus on the upcoming catalysts. Smart money (RA Capital, Viking, Deep Track, etc.) piled in for a reason — they see real potential in this dual-agonist for liver and metabolic diseases. Classic early-stage biotech setup: high risk, but the capital injection removes a major worry and sets up the next leg higher if the data delivers.” Short, straightforward, and realistic no hype, just the setup. 4k on May 15 2.5 C

Used_Salamander_3532

Altimmune (ALT) just closed a big $225M oversubscribed funding round in late April, giving the company a solid runway to push its lead drug pemvidutide into Phase 3 for MASH. With Q1 earnings coming up on May 13, the stock looks primed for a bounce back toward the $5–6 zone as the financing overhang clears and investors focus on the upcoming catalysts. Smart money (RA Capital, Viking, Deep Track, etc.) piled in for a reason — they see real potential in this dual-agonist for liver and metabolic diseases. Classic early-stage biotech setup: high risk, but the capital injection removes a major worry and sets up the next leg higher if the data delivers.” Short, straightforward, and realistic no hype, just the setup. 4k on May 15 2.5 C

Used_Salamander_3532

ALT has strong short squeeze setup with ~28.7M shares short (~22% of float) and 9–14 days to cover. After the post-offering dip near $2.6, any positive May 13 earnings or clinical news could ignite covering and push it toward $5+. Dilution impact is softened because the $225M raise was a stock + warrant combo at $3 attracting long-term bulls who have incentive to hold or exercise higher rather than dump shares immediately.

thenorthernwhiteboy

Goodluck brother, I actually like the science too. In this ALT and SLS. Just for those who don’t do their research. I’m down huge on my shares so I’m gonna avg down slightly and grab some leaps

Used_Salamander_3532

ALT - time has come . Earning 15th MAy

Used_Salamander_3532

And ALT please , just bought weekly calls

Used_Salamander_3532

Altimmune Inc. (NASDAQ:ALT) is focused on the development of innovative peptide-based therapeutics for people suffering from serious illnesses like liver diseases, chronic hepatitis B, NASH, and obesity. Its primary product candidate is pemvidutide, currently in phase 3 of the clinical trial. Additionally, it has completed the MOMENTUM Phase II obesity study and is currently being evaluated in the IMPACT Phase IIb MASH trial.

Used_Salamander_3532

Altimmune Inc. (NASDAQ:ALT) is focused on the development of innovative peptide-based therapeutics for people suffering from serious illnesses like liver diseases, chronic hepatitis B, NASH, and obesity. Its primary product candidate is pemvidutide, currently in phase 3 of the clinical trial. Additionally, it has completed the MOMENTUM Phase II obesity study and is currently being evaluated in the IMPACT Phase IIb MASH trial.

_RAPTORMAN_

There are none over there!!! ALT+F4 that hoe

WeirdChocolate4625

What are current thoughts on ALT? Any news on this stock?

G0RD0N_CLARK

Found George W’s ALT account everyone

existing-entity

Tell that to billion dollar hedge funds and ALT funds as well as the most advanced quant models that use math equations you’ve never seen in your live to build price and risk models. But fundamental is also important, then vibes. All 3 are important and work together as confirmation for your trade thesis, you’d know this if you read a finance/trading book

KnickersTwisted

I'm throwing good money after bad on ALT. That product is going to make a big difference in people's health outcomes.

TXtogo

They should buy ALT and bring that shit through phase 3

KnickersTwisted

!banbet ALT $5 1d

KnickersTwisted

Calls on ALT, anyway.

OptionsHuduga

Anyone here gonna play ALT, PDYN, AMPX for earnings?

KnickersTwisted

Lol, no, I meant did you do that buying ALT?

KnickersTwisted

ALT?

Nikante

Try pressing “CTRL ALT DEL” buttons at the same time.

KnickersTwisted

IBRX printed, and I'm rolling it for earnings March 2nd. Also, ALT.

Responsible-Library8

Buy call options for ALT expiration March 20th. Not Financial Advice of course. (:

TXtogo

They have a large base of customers so they can accelerate compiling the candidates for a trial, which is one of the longer processes. A company like ALT has already been approved for phase 3, already approved for fast track designation as a breath through drug - it’s sort of a no-brainer to partner with a company like this.

ThrowRA-hamburger

the AI musical chairs thing is exactly why im skeptical of US equities rn. been looking at solid ALT projects like SEI lately since its way off highs and could catch up if market rotates

Unlucky_Battle_6947

$ALT is 5.60 and should hit around 12-17

Ok_Cartoonist6749

MIST Zacks #1 buy in commercial stage. RMTI ZACKS #2 buy ER on line n new COO N SIGNIFICANT improvement in clients. ALT got Institutual dilution will go up after feb/Mar rite now accumulate zone. VOYG pull back defence+space+NASA

K2centaur49

100% agree with EVERYTHING you said here. Great sum up Ive been in ALT 2 years screaming at everyone I know pounding the table seeing exactly what you see is that the market is missing this one !🥳

Ok_House1566

ALT. REG\_SHO and... https://preview.redd.it/l71ecu4ow5gg1.png?width=1153&format=png&auto=webp&s=23ae766eb1401112e0d4b8172a7e6e60a854cced

Gristle__McThornbody

My ALT calls are absolutely fucked.

7Billiards

Holding ALT. Got a nice Overweight rating from Barclays should pump harder

Friendly-Profit-8590

All I’m getting from the discourse here is that ALT is either a diamond in the rough or a dumpster fire in the making. So basically it’s no different than any number of other small time pharmaceutical companies. It’s a scratch off ticket where your best odds are to hopefully get your money back. That said I’m a gambler so fuck it.

KnickersTwisted

If you aren't buying ALT like you missed ASTS when it was $2 a share then you haven't been paying attention.

Nobsy8

Why am I certain that there will be a huge short squeeze today? 1. The "Squeeze Zone" ($5.50 to $6.00) We are currently sitting exactly at the critical threshold. * Current Price: $5.50 (slightly higher at $5.53 in after-hours trading). * The Market Maker Dilemma: A large volume of Call options with strike prices of $5.00 and $5.50 are now "In-the-Money" (ITM). This means the banks and institutions that sold these contracts must now aggressively buy shares to hedge their positions. * Next Resistance: The $6.00 mark. If ALT breaks above $6.00 on Monday, the sellers of the $6.00 Calls will come under extreme pressure. 2. Signals for Monday (Checklist) Watch these three metrics on Monday to determine if the Gamma Squeeze is igniting: | Metric | Normal Value | Squeeze Signal (Alert!) | |---|---|---| | Trading Volume | ~ 4–5M shares | > 10–15M shares | | Stock Price | $5.50 | Break above $6.00 | | Call Volume | ~ 9,000 contracts | > 20,000 contracts | 3. What’s happening behind the scenes? Market makers utilize Delta Hedging. As the stock price rises, the "Delta" of the options (the probability of them expiring ITM) increases. To maintain a neutral position, they must increase their hedge by buying more shares. Gamma measures the rate at which this Delta changes—and for ALT, Gamma is currently very high because many options are nearing their February expiration.

hawthst

$ALT 1/30 $6 Calls

PolicyAdmirable

I run a small device startup university spinout with an early indication for MASH and have compared our therapy in early preclinical studies to just about every MASH prospect out there and pemvidutide is clearly the most promising as a dual agonist (not my take, this is what our university lab researchers believe). The billion dollar Akero and 89bio (bought after phase 2) deals are a tailwind for us, but even just looking at Rezzdiffra (Madrigal) as a comp this drug has exceeded $1B ARR in just a year DESPITE the fact that it's $40k/yr and only 30% of patients respond to it. You never know with pharma, but yeah this is the one I'm bullish on and I've only lost money on Madrigal I think because of the broader rotations into $ALT. We will see!

CareAgitated7519

“He was a very respected and competent CEO” Dude. No. So much of what’s wrong with ALT and it’s SP is because of him. The marker hated him, as did us bag holders. Hard to trust you know anything about this stock when you make this statement lmao. Durso taking over was a fucking lifeboat for this stock

Dritzz-9966

They are struggling, this is a fact. They do not currently have enough cash on hand for Phase 3 (which is why it still has not started and why management said they are waiting for a partner). Nobody is hating. As I said, the drug works. If ALT had a secure financial position (I'm talking at least $750M), I would be more bullish.

kantargi

ALT gang?

DialSquar

the $ALT guy was right

wolvendael

and to tackle this misinfo point by point, in the name of good DD, not FUD: \- ALT has $250m cash on hand and a $100m credit facility from Hercules. They have plenty of cash to fully enroll p3 and possibly even go it alone, since their talks with FDA on p3 are aligning on a dual p3 of biopsy (900 patients) and noninvasive tests (900 patients). That will cut down their p3 costs tremendously compared to someone like BI (survodutide) who is enrolling 1800 biopsy patients). Further, ALT is the first company to use PathAI in their biopsy workflow - which according to the data in the FDA approval packet from PathAI, will great reduce false negatives and speed enrollment) \- The precious CEO was a 'science CEO' and did just fine bringing the molecule through p2. Now they moved to a 'commerical CEO' who knows how to sell the drug. \- Weight loss: in ALT's obesity trial, the max dose (2.4mg) hit -15% WL with just 21% from lean muscle mass - using the same MRI bosy composition analysis used by LLY, NVO and others. Its true that the 1:1 glucagon to GLP ratio isn't optimized for weight loss, but this is certainly competitive and enough for MASH drug, where hepatologists are simply looking for 8-10% WL to complement the direct liver actions. MASH market is 9m F2-F3 patients - smaller than obesity but the reimbursement for a MASH drug is significantly higher: resmetirom is $47k per patient year. \- Madrigal is doing great building out the MASH market, which is stil nascent, but it's far from being "the king". Of the 9m MASH patients, they have captured 30k. There's a lot of room left in this market. tirzepatide and reta are doing a 5 year outcome study - so they won't be to market until the early 2030s. Survodutide is in p3, but they had a 20% d/c rate in phase 2 - making it intolerable. pemvi is the next man up for F2-F3 patients, offering results better than resmetirom, more tolerable than sema, and both direct liver action and weight loss. It has a very favorable product profile and should be very welcome in the market.

Ornery_Effective_106

This will be ALT ‘s closing price on January 30th

wolvendael

So this is gaslighting 101 by a VKTX baggie. No stock has a bigger cult following than VKTX. How many times have you heard of ALT? My guess is few and far between - hence it doesn’t pass the smell test that it has a cult following. ALT does have a few followers who objectively look at very good science and differentiating factors that continue to be ignored by WS and bashed by competitors. The truth about pemvidutide: it’s a 1:1 glucagon to GLP agonist, which skews it less towards max weight loss (-15% in its straight obesity trial) and better suited for MASH. It had its phase 2 results (which weee excellent) published in The Lancet, has late-breaker podium presentation at the largest hepatology conference in Nov, receive BTD from the FDA for phase 3, has a new commercially-focused CEO, and is now likely in talks with a partner. Yet it barely sits above cash value. That is what ALT investors are focused on - the mispricing or deliberate suppression of the share price. The competitive landscape favors pemvidutide: it has the classic MASH and fibrosis response of other drugs in its class, but it has BIC tolerability. This is what matters most in MASH: staying on the drug. Hepatologists and GIs have repeatedly said that they are not chasing weight loss. It’s nice to have, but GLP1s that have 10-20% diacontinuations (like survodutide) are not going to be prescribed. Patients have a serious liver disease and have to remain on the drug. Pemvi has <1% tolerability, mainly due to its EuPort construction, which slows absorption and decrease max concentration. This is a large differentiating factor for pemvi. After that, its results with prescriber-preferred noninvasive tests (VCTE, ELF, PDFF) were so good and statistically significant that the global head of MASH for Lilly called them “beautiful” at AASLD conference in Nov. and now FDA is moving away from biopsy and allowing NITs for pivotal trials - right at the perfect time for ALT’s p3 design. ALT bulls aren’t trying to convening you that pemvidutide will be the number 1 drug of all time, or that it will replace all other MASH drugs. It’s simply that pemvidutide does seem poised to capture a lot of the market, has been derisked due to FDA BTD (conferring a historical 80% prob of success from a Jefferies analysis), and that every other drug entering p3 in MASH with good data and BTD has been bought for $3bn to $5bn. It’s a hot field. There are many legacy players with no presence - including GSK, AZ, PFE, and many others looking to get into the MASH field. ALT longs would simply like to see the company rerate to fair value. It’s certainly long overdue.

Ok_Cartoonist6749

RMTI ( Turn around ER) to 5 ( had pullback 1.15) ALT....to 20 MIST...to 12 VOYG (Space & Defence) to 75

Dry_Roof6413

A few clarifications for balance: Cash & P3 funding ALT ended last quarter with enough runway into 2026, and management has clearly guided that they are in active partnering discussions for Pemvidutide in MASH and cardiometabolic indications. In biotech, partnering before Phase 3 is actually leverage, not weakness — it allows risk-sharing while retaining significant upside. Dilution is one option, not the base case. CEO transition The prior CEO did not “leave abruptly.” This was a planned transition, and the current leadership team is deeply experienced in late-stage development and partnering. Board and insiders remain heavily aligned. Weight loss vs MASH positioning Pemvidutide is intentionally optimized for fat loss with muscle preservation, not just scale weight. In MASH, this is critical because rapid lean mass loss (seen with pure GLP-1s) worsens frailty and long-term outcomes. ALT’s data show: Significant liver fat reduction Meaningful fibrosis improvement signals Best-in-class lean mass preservation vs GLP-1 / GIP agents That combination is exactly what regulators and hepatologists are looking for in a chronic MASH therapy. Competitive landscape Tirzepatide and retatrutide show promise, but they are broad metabolic drugs being tested in MASH. Pemvidutide is a purpose-built dual GLP-1 / glucagon agonist designed specifically for: Hepatic fat oxidation Mitochondrial activity Anti-fibrotic pathways This is a differentiated mechanism, not a me-too GLP-1. Market size MASH is projected to be a $30B+ market this decade, with multiple winners. Even modest penetration with premium pricing supports multi-billion dollar peak sales. A clean safety profile + muscle preservation gives Pemvidutide strong partner appeal. Valuation disconnect At current market cap, the stock is pricing in: Failure to partner No Phase 3 success No strategic interest Yet Phase 2 data already showed: Clinically meaningful MASH resolution signals Competitive weight loss Best-in-class body composition That risk/reward skew is exactly why long-term biotech funds are accumulating here, not shorting. This isn’t cult behavior — it’s simply recognizing a deeply undervalued late-stage metabolic asset with multiple shots on goal and clear strategic value to big pharma hunting for the next MASH backbone therapy. “Calling it a ‘cult’ doesn’t change the data, and setting a $0 PT while admitting partnership talks are ongoing just exposes the bias. Fundamentals, not feelings, decide biotech outcomes, and right now the science is speaking a lot louder than the salt.”

2Hosslovescash

Is moar another ticker? If not, I’ll buy MORE ALT shares.

TTP222

ALT is going to trial a higher dosage in Phase 3 that should lead to more weight loss. Compounds with glucagon are going to be the future of weight loss and MASH.

Dritzz-9966

I coudn't agree more. A lot of people in ALT are in there because of technicals, or because it's heavily pumped on social media, and they lack knowledge in pharma so they don't see the red flags. Pemvidutide absolutely won't be a weight loss drug. There's nothing competitive about it, at all. The one thing they latch unto is the muscle mass preservation, which, as you said, doesn't really matter. Also, realistically, what will happen will be pts will do the initial WL with a subq agent (tirzepatide, VK2735,...) and will then move on to a PO agent for maintenance, at low doses. I'm mainly thinking about VK2735 subq into PO VK2735 because it appears to be the most promising to me, placebo-like tolerability profile. And even if you lost a little more muscle in the initial WL with the subq agent, you will have the opportunity to build it back on the PO maintenance agent (or low dose subq agent as maintenance). That's why I believe the muscle mass argument just doesn't really make sense if you think about it.

Dry_Roof6413

BTD + strong Pemvidutide data already make $ALT a prime MASH/obesity play. Add to that the JPM Healthcare whispers of partnership or even buyout interest, and this starts looking like a real takeout setup. Sub-$1B valuation with Big Pharma circling = coiled spring. One deal headline and this goes vertical. 🚀💎

KrumpyKitty

How about this, ALT is headed for a >$10B buyout!

7Billiards

Got called Chinese today and I’m not even chinesemaxxing. It’s going to be a good day for ALT

KrumpyKitty

ALT is headed to the moon, I’m in!

Dritzz-9966

Please, I cannot stress this enough, people need to do adequate research before investing. Do not invest only because of a Reddit post. Technicals do not matter for biotech stocks so let's instead look at factual data. For the financials: ALT is in a very struggling position, very low cash on hand, not enough to fund their P3, they are instead waiting for a partner (as per CEO). This means there is much less leverage if partnership/buyout. It also means if they can't partner, they will have to massively dilute, up to 25-35% of their market cap to fund P3 until approval. Not an ideal situation. For weight loss: Pemvidutide does not appear to be competitive on weight loss. It's extremely low vs even semaglutide, and that's without even talking about the big boys tirzepatide, retatrutide, VK2735. Pemvidutide IS NOT a weight loss drug. It is a MASH drug. This was corroborated by management, they are only pursuing MASH and not weight loss. This means the potential market is much, much, much smaller than the weight loss market. For MASH: Pemvidutide as I said is a MASH drug. It will sell if approved, sure. How much? That's the question. I'd argue not much. MDGL is currently the king in this market. However, the thing that's still not talked about is the fact that tirzepatide and VK2735 both appear to have a more significant effect on MASH than pemvidutide, and those are WL drugs. So a two-in-one. What does pemvidutide have that the others do not? They appear to have slightly better muscle preservation according to early studies but it wasn't really expanded upon, so very hard to say if this impact is significant. I am not shorting ALT currently, but I don't believe in the company long term. My price target is $0 by 2030 if GIA is pursued and they can't partner. If they can partner, then the target is maybe $6-8. Not much more than that.

Hot-Ambassador8740

The $ALT post on the main page is 100000% being posted and run by Chinese scammers.

OGDocHollywood

💀💀💀💀💀💀💀💀 Former $ALT bull here. Positions shared on Afterhour (user Doc Hollywood) I want to express caution to everyone here. I lost on this trade because the MASH trial data showed that although pemvidutide had some positive effects, it failed to hit a statistically significant improvement on the key fibrosis endpoint versus placebo — a major goal for liver disease drugs. This gives me $SAVA vibes (another loser for me) and I caution others to avoid.

dlaff1

Beware of calls on ALT. I trade a lot of options and don’t recommend ALT options because the volume is too low for the number of dates/strikes. The spreads are too wide and the cost to get in and out will wreck you unless this moons. The upside is very good on shares alone so consider that. Higher volume stocks option are great though. Just my $0.02.

Responsible-Library8

Take a look at my DD on ALT page or personal page. I couldn’t share it here. But think you will be very happy with your investment.

Apegg

ALT looks ready to pop.  10% yesterday, 16% today, 3% AH.  Price targets are all 18+ for this 2nd gen GLP1 glucagon molecule. Break through designation awarded by the FDA jan5. Entering phase 3 and need a strategic transaction  soon.  Load up

TXtogo

ALT looks like it is finally moving, up big today and a lot of AH volume.

ProsperousGerman

Seriously. He’s the bag holder. Altimmunes showing way better results. Only reason pemvi wouldn’t be used compared to rezdiffra is for people who aren’t overweight. ALT for the win!

7Billiards

ALT moonshot

Zebranazgul

Sell INTC and buy ALT instead

Justiceenforcer4711

$ALT - the Data is very positive and compared to competition they are undervalued by at least 12x

Responsible-Library8

The 48W data was great. The drop due to dealer exposure is what caused the average retail investor to think it was "mid". Look at the attention pemvidutide has gotten from reputable sources (scientist, academic journals, analyst, FDA). Following 48W data, they recieved BTD for P3. ALT's milestone catalyst have been muted and my above post explains why. Also Dec 19th Reg-SHO hit, supporting the abuse of shorting on the stock to prevent it from running away from dealers control that was already maxed out.

ohgodthehorror95

When the price collapses after the 48 week data readout, couldn't that just as easily be attributed to muted investor sentiment? This isn't the first time ALT has been bid-up leading into a binary event. And historically its reverted to the mean afterward when the data turns out to be just *okay.* Not bad, not great, just mid. Their clinical data wasn't terrible, per say. But for investors who were really **really** getting their hopes up, it was probably a bit underwhelming. Just my shot in the dark interpretation

Ok_Cartoonist6749

NOT Penny MIST, ALT

Ok_Cartoonist6749

VOYG ,ALT, MIST.. VOYG DEFENCE N SPACE. ALT had been consolidating at 4.0 with FDA MASH Approval. MIST REDDIT FDA approval for PSTV.

Jury-Altruistic

ALT and GUTS serves two different customer base in the weight loss market mate

Unique_Durian5944

ALT5?

Ok_Cartoonist6749

1. ALT Positive phase=3 Analyst SP=18 https://finance.yahoo.com/news/does-altimmune-alt-potential-rally-145502324.htm 2. There was pull back so gr8 entry n insider purchase. 2026 is FOR ALT.

Ok_Cartoonist6749

Or buy ALT with today news of their Drug

Master-Vanilla-5625

ALT at 4.20 now, even better

Master-Vanilla-5625

SLS profit now at 4.70, buy ALT at 4.30 sell at 4.50+ reenter SLS is a play SLS seems to be topping of for now

shaqballs

I spammed here about SLS when it was under $2 (it’s nowhere close to being done) but anyone looking for different plays should look at ALT stock. They have a weight loss drug that is actually better at treating fibrosis. Just got fast track designation for their drug and it’s about 1/10th of the SP that it should be. Buyout will be 5-10b when it comes

Uplipht

ALT might run up close to $5 based off of previous December prices.

ankur1088

ALT Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Uplipht

Hoping ALT can retrace back up to that $5 mark

BigElvis_Gtown

ALT. BIO on the move imo. Been invested since 2023. Great trend in science and waiting on FDA minutes and release of P3 plan.

StrawberryOk8459

Well they better buy ALT because pemivutide is coming for their market share with a better drug.

InterestingMinute972

What makes you think ALT will rebound? It jumped up, then came back to the levels it was about 1.5 months ago. Doesn't seem like a huge drop that warrants definite reversal. I'm genuinely curious as this was a ticker I followed earlier this year

Ilovebadjokes

SLS ACET depending on what RS decision is. ALT for the rebound

Ilovebadjokes

Bios- ALT is now a penny again and sold on news, probably a good time to buy. ACET is oversold, voting on RS but they have until April for compliance and have stated they want to wait to see if stock price will naturally go up with Q1 updates. SLS is just a great company and that is easy gains.

OutOfMyComfortZone1

The market makes absolutely zero fucking sense. Pemvidutide phase 2b trial results come in this morning with huge positive results, and what happens? ALT plummets 20 fucking percent. None of this makes sense

Johnwicker27

ALT had some positive news for its trial, it spiked a while ago and is currently down 2.5 %.Could be a good price to buy in. Kinda weird that it’s trading lower than its lowest price all month. While I’m writing this it’s already up a bit more so only down about 1% now

Butter_Ball22

Has anyone tried just pressing CTRL+ALT+DEL to reboot the market yet… Or just clearing out its Cache?

Correct_Proposal_409

Okay. fair comment, since elevated liver enzymes are common with early oral small-molecule trials. But there was only one case of transient elevated liver enzymes in the 1b trial, and they withheld dosing, then reduced the dose and the enzymes normalized and stayed in normal range. And the only other case (of 77 people) was in the 1a trial and it was a mild increase: "One subject had a transient, mild increase in AST and ALT after receiving a single dose of GT-02287". No SAE's.

benjamin_noah

Sure. As I also said before, I am concerned that the trials have shown that GT-02287 causes elevated liver enzymes (ALT, AST, and alkaline phosphatase). Which, for what would be a long-term medication, could be problematic. But I believe there's also some evidence those levels could normalize over time. So, that feels like a normal biotech risk. I don't like that I've never seen either of you address that in your posts.

Old-Discussion3777

$ALT Altimmune should be a top ten trending stock of the week. This is a great summary and highly recommend the read. One thing to make clear is there is no fibrosis readout from biopsy at 48 weeks. That is what could pump the breaks on a massive rally. Also safety and tolerability will be in huge focus and should be stellar based on 24 weeks but needs to be watched still. The 24 weeks data was awesome to those of us who have been in and around MASH data readouts but missed stat sig. I’m surprised the company was so aggressive, even four more weeks may have been just enough to tip the scales since if you think about liver fibrosis improving, that’s literally the liver regrowing and healing parts of itself from a scar. Think about scars from cuts you get. It takes time. Good luck to all! I’m fully loaded.